Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Key Points Interested in Candel Therapeutics, Inc.? Here are five stocks we like better. Candel Therapeutics said it remains on track to file a BLA by year-end for aglatimagene in localized prostate ...

A new study has highlighted a significant knowledge gap among patients about repeat radiotherapy (reirradiation) as a treatment option for recurrent prostate cancer ...

Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63,000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward ...

Men given two larger doses of radiation had about the same side effects as others treated with the standard five-dose course, ...

Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...

An investigator presented extended follow-up data from a phase 3 trial on aglatimagene besadenovec (CAN-2409) + prodrug in combination with standard-of-care EBRT in men with localized prostate cancer.

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...